1 active not recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow CD30-Positive Neoplastic Cells Present: new trials by email Literature Review of CD30-Positive Neoplastic Cells Present trials Research Report on CD30-Positive Neoplastic Cells Present
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis - Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present | Phase 1 / Phase 2 | Withdrawn | University of Washington | 2018-01-03 | 2019-10-10 | |
| Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery Brentuximab Vedotin, Laboratory Biomarker Analysis - CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2017-04-05 | 2026-08-25 |
Lymphoma, Large-Cell, Anaplastic (1) · Mesothelioma, Malignant (1)
Neoplasms (2) · Neoplasms by Histologic Type (2) · Adenoma (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lung Diseases (1) · Lung Neoplasms (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoproliferative Disorders (1) · Mesothelioma (1) · Neoplasms by Site (1)
Brentuximab Vedotin (2) · ceritinib (1)
M.D. Anderson Cancer Center (1) · University of Washington (1)
United States (2)
Andrei Shustov (1) · Anne S Tsao (1)
P30CA015704 (1)